全文获取类型
收费全文 | 319篇 |
免费 | 19篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 5篇 |
妇产科学 | 10篇 |
基础医学 | 52篇 |
口腔科学 | 3篇 |
临床医学 | 25篇 |
内科学 | 76篇 |
皮肤病学 | 7篇 |
神经病学 | 35篇 |
特种医学 | 10篇 |
外科学 | 34篇 |
综合类 | 18篇 |
预防医学 | 31篇 |
药学 | 23篇 |
肿瘤学 | 7篇 |
出版年
2024年 | 1篇 |
2023年 | 7篇 |
2022年 | 22篇 |
2021年 | 25篇 |
2020年 | 9篇 |
2019年 | 16篇 |
2018年 | 14篇 |
2017年 | 7篇 |
2016年 | 13篇 |
2015年 | 7篇 |
2014年 | 21篇 |
2013年 | 17篇 |
2012年 | 23篇 |
2011年 | 30篇 |
2010年 | 16篇 |
2009年 | 8篇 |
2008年 | 19篇 |
2007年 | 12篇 |
2006年 | 13篇 |
2005年 | 7篇 |
2004年 | 17篇 |
2003年 | 12篇 |
2002年 | 12篇 |
1997年 | 1篇 |
1994年 | 1篇 |
1988年 | 1篇 |
1986年 | 3篇 |
1985年 | 1篇 |
1984年 | 4篇 |
排序方式: 共有339条查询结果,搜索用时 281 毫秒
101.
102.
Faiza Ahmed Jennifer Onwumeh-Okwundu Zeynep Yukselen Maria-Kassandra Endaya Coronel Madiha Zaidi Prathima Guntipalli Vamsi Garimella Sravya Gudapati Marc Darlene Mezidor Kim Andrews Mohamad Mouchli Endrit Shahini 《World journal of gastrointestinal oncology》2021,13(11):1813-1832
BACKGROUNDDespite the use of current standard therapy, the prognosis of patients with unresectable hepatocellular carcinoma (HCC) is poor, with median survival times of 40 mo for intermediate HCC (Barcelona Clinic Liver Cancer [BCLC] stage B) and 6–8 mo for advanced HCC (BCLC stage C). Although patients with early-stage HCC are usually suitable for therapies with curative intention, up to 70% of patients experience relapse within 5 years. In the past decade, the United States Food and Drug Administration has approved different immunogenic treatment options for advanced HCC, the most common type of liver cancer among adults. Nevertheless, no treatment is useful in the adjuvant setting. Since 2007, the multi-kinase inhibitor sorafenib has been used as a first-line targeted drug to address the increased mortality and incidence rates of HCC. However, in 2020, the IMbrave150 trial demonstrated that combination therapy of atezolizumab (anti-programmed death-ligand 1 [PD-L1]) and bevacizumab (anti-vascular endothelial growth factor [VEGF]) is superior to sorafenib, a single anti-programmed death 1/PD-L1 antibody inhibitor used as an anti-cancer monotherapy for HCC treatment.AIMTo conduct a systematic literature review to evaluate the evidence supporting the efficacy and safety of atezolizumab/bevacizumab as preferred first-line drug therapy over the conventional sorafenib or atezolizumab monotherapies, which are used to improve survival outcomes and reduce disease progression in patients with unresectable HCC and non-decompensated liver disease. METHODSA comprehensive literature review was conducted using the PubMed, Scopus, ScienceDirect, clinicaltrials.gov, PubMed Central, Embase, EuropePMC, and CINAHL databases to identify studies that met the inclusion criteria using relevant MeSH terms. This systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and risk of bias (RoB) were assessed using the Cochrane RoB 2 tool and Sevis.RESULTSIn the atezolizumab/bevacizumab group, an improvement in overall tumor response, reduction of disease progression, and longer progression-free survival were observed compared to monotherapy with either sorafenib or atezolizumab. Hypertension and proteinuria were the most common adverse events, and the rates of adverse events were comparable to those with the monotherapy. Of the studies, there were two completed trials and two ongoing trials analyzed using high quality and low bias. A more thorough analysis was only performed on the completed trials.CONCLUSIONTreatment of HCC with atezolizumab/bevacizumab combination therapy was confirmed to be an effective first-line treatment to improve survival in patients with unresectable HCC and non-decompensated liver disease compared to monotherapy with either sorafenib or atezolizumab. 相似文献
103.
104.
Ahnadi CE Boughrassa FF Chapman-Montgomery ES Poisson V Gervais A Okrongly D Grant AM 《Thrombosis and haemostasis》2004,92(6):1207-1213
The study investigated the clinical usefulness of a new method to evaluate platelet activation and the variability of platelet response to anti-platelet therapy in patients undergoing percutaneous transluminal coronary angioplasty (PTCA). Platelet activation was assessed in parallel by a new method for platelet density measurements (MPC, Mean Platelet Component Concentration), on the automated ADVIA 120 Hematology System and by the classic measurement of P-selectin (CD62P) expression, on a fluorescence flow cytometer. Patients received a loading dose of clopidogrel (300 mg; n = 29) or a bolus of abciximab (0.25 mg/kg; n = 15). Blood samples were collected before (baseline) and at different times after PTCA and antiplatelet drugs administration. Our data showed a close inverse correlation between the change in MPC and the CD62P fluorescence surface marker expression (r = -0.776, P<0.0001). Individual platelet activation determinations in patients receiving either clopidogrel or abciximab showed a variation in platelet activation as assayed by MPC and CD62P expression. Patients were characterized as having either high platelet activity upon admission and positive response to treatment or no detectable platelet activation before or after treatment. This study demonstrates the heterogeneity of platelet activation states in ACS patients undergoing coronary angioplasty. The present work also illustrates the potential use of the MPC parameter, generated on an automated hematology system, to define high risk patients and to monitor the variability of platelet response to anti-platelet therapies. 相似文献
105.
Qari FA 《Saudi medical journal》2003,24(6):675-676
A 45-year-old Indian patient with a history of type 2 diabetes mellitus presented with history of pain in the left side of the neck associated with sore throat of one month duration. The diagnosis of subacute granulomatous thyroiditis (de Quervains thyroiditis) was made which was confirmed radiologically by depressed radioactive iodine uptake. The patient showed marked clinical response and improvement within 24 hours on anti-inflammatory drugs and corticosteroid. 相似文献
106.
Use of zwitterionic detergent for the preparation of an influenza virus vaccine. 1: Preparation and characterization of disrupted virions 总被引:1,自引:0,他引:1
Catriona R. Crawford Faiza A. Mukhlis R. Jenning J.S. Oxford D.J. Hockley C.W. Potter 《Vaccine》1984,2(3):193-198
The zwitterionic, Empigen BB an alkylbetaine based on a C12-C14 alcohol was shown to disrupt influenza A and B viruses in such a way as to retain the biological activity of the surface haemagglutinin (HA) and neuraminidase (NA) antigens. The optimal conditions required to obtain the maximum recovery of HA and NA activity from purified influenza X47 (H3N2) virus concentrate after treatment with Empigen, and the nature and the morphological appearance of the Empigen-treated preparations both before and following a sucrose density gradient purification step, are described. Matrix (M) protein was readily removed during purification, but nucleoprotein (NP) could not be separated from the surface protein activity. 相似文献
107.
108.
Faiza Mougari Laurent Raskine Agnes Ferroni Estelle Marcon Isabelle Sermet-Gaudelus Nicolas Veziris Beate Heym Jean-Louis Gaillard Xavier Nassif Emmanuelle Cambau 《Journal of clinical microbiology》2014,52(6):1969-1977
Mycobacterium abscessus is a rapidly growing mycobacterium that causes respiratory tract infections in predisposed patients, such as those with cystic fibrosis and nosocomial skin and soft tissue infections. In order to investigate the clonal relationships between the strains causing epidemic episodes, we evaluated the discriminatory power of the semiautomated DiversiLab (DL) repetitive extragenic palindromic sequence PCR (REP-PCR) test for M. abscessus genotyping. Since M. abscessus was shown to be composed of subspecies (M. abscessus subsp. massiliense, M. abscessus subsp. bolletii, and M. abscessus subsp. abscessus), we also evaluated the ability of this technique to differentiate subspecies. The technique was applied to two collections of clinical isolates, (i) 83 M. abscessus original isolates (43 M. abscessus subsp. abscessus, 12 M. abscessus subsp. bolletii, and 28 M. abscessus subsp. massiliense) from infected patients and (ii) 35 repeated isolates obtained over 1 year from four cystic fibrosis patients. The DL REP-PCR test was standardized for DNA extraction, DNA amplification, and electrophoresis pattern comparisons. Among the isolates from distinct patients, 53/83 (62%) isolates showed a specific pattern, and 30 were distributed in 11 clusters and 6 patterns, with 2 to 4 isolates per pattern. The clusters and patterns did not fully correlate with multilocus sequence typing (MLST) analysis results. This revealed a high genomic diversity between patients, with a discriminatory power of 98% (Simpson''s diversity index). However, since some isolates shared identical patterns, this raises the question of whether it is due to transmission between patients or a common reservoir. Multiple isolates from the same patient showed identical patterns, except for one patient infected by two strains. Between the M. abscessus subspecies, the indexes were <70%, indicating that the DL REP-PCR test is not an accurate tool for identifying organisms to the subspecies level. REP-PCR appears to be a rapid genotyping method that is useful for investigating epidemics of M. abscessus infections. 相似文献
109.
Anticyclic Citrullinated Peptide Antibody and Rheumatoid Factor in South Tunisian Patients With Rheumatoid Arthritis: Association With Disease Activity and Severity
下载免费PDF全文
![点击此处可从《Journal of clinical laboratory analysis》网站下载免费的PDF全文](/ch/ext_images/free.gif)
110.